A5000198604- Prostate Cancer Treatment and Research
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
- Vitamin C and Antioxidants Research
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Prostate Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Hypoxia, and Metabolism
- Renal and related cancers
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Esophageal Cancer Research and Treatment
The Barbara Ann Karmanos Cancer Institute
2016-2025
Wayne State University
2016-2025
Mayo Clinic
2007-2025
Mayo Clinic in Arizona
2025
WinnMed
2025
Johns Hopkins University
2000-2024
University Hospitals Seidman Cancer Center
2024
Sidney Kimmel Comprehensive Cancer Center
2002-2024
Anne Arundel Medical Center
2024
University Hospitals of Cleveland
2024
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about impact this heterogeneity on clinical outcome. Here, we report and transcriptomic analysis 429 patients with castration-resistant (mCRPC) linked longitudinal outcomes, integrating findings from whole-exome, transcriptome, histologic analysis. For 128 treated a first-line next-generation androgen receptor signaling inhibitor (ARSI;...
Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated platinum and anti-programmed death 1 ligand (PD-1/L1) therapy. Enfortumab vedotin antibody-drug conjugate that targets Nectin-4, which highly expressed in carcinoma.EV-201 a global, phase II, single-arm study of enfortumab 1.25 mg/kg (intravenously on days 1, 8, 15 every 28-day cycle) locally chemotherapy anti-PD-1/L1 The primary end...
Clinical trials that study cancer are essential for testing the safety and effectiveness of promising treatments, but most people with never enroll in a clinical trial - challenge exemplified racial ethnic minorities. Underenrollment minorities reduces generalizability research findings represents disparity access to high-quality health care.Using multilevel model as framework, potential barriers enrollment were identified at system, individual, interpersonal levels. Exactly how each level...
PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers microtubule-disrupting agent, monomethyl auristatin E, to cells express Nectin-4. METHODS EV-101 is phase I dose escalation/expansion study enrolled patients with Nectin-4–expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on ≥ 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death...
17 Background: ARV-110 is a first-in-class, oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets AR. Patients (pts) with mCRPC have limited treatment (tx) options due to decreasing AR dependence of tumors upon successive therapies. Previous phase 1 data indicated clinical activity for in heavily pretreated pts and suggested enhanced specific molecular profiles, eg, T878 H875 mutations, leading 2 expansion (ARDENT) further characterize biomarker-defined pt...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
The emergence of castrate-resistant prostate cancer (CRPC) contributes to the high mortality patients diagnosed with (PCa), which in part could be attributed existence and stem cells (CSCs). Recent studies have shown that deregulated expression microRNAs (miRNAs) initiation progression PCa. Among several known miRNAs, let-7 family appears play a key role recurrence PCa by regulating CSCs; however, mechanism aggressiveness is unclear. Enhancer Zeste homolog 2 (EZH2), putative target family,...
Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor. We conducted a phase I, first-time-in-human, clinical trial using escalating doses of foretinib. The primary objectives are to identify maximum tolerated dose determine the safety profile Secondary included evaluation plasma pharmacokinetics, long-term after repeated administration, preliminary antitumor activity, pharmacodynamic activity.Patients had histologically confirmed...
Abstract Purpose: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models. A two-stage phase II study was conducted to assess the and toxicity profile of 17-AAG administered patients metastatic, hormone-refractory cancer. Experimental Design: Patients at least one prior systemic therapy rising prostate-specific antigen (PSA) were eligible. received dose 300 mg/m2...
Barrett's esophagus is a premalignant condition that risk factor for the development of esophageal adenocarcinoma, disease whose incidence rapidly increasing. Because aspirin and other nonsteroidal anti-inflammatory drugs, such as celecoxib, may decrease developing cancer, we investigated effect long-term administration celecoxib in patients with dysplasia. Chemoprevention Esophagus Trial (CBET) phase IIb multicenter randomized placebo-controlled trial low- or high-grade Patients were...
Abstract Background. The antifungal drug itraconazole inhibits angiogenesis and Hedgehog signaling delays tumor growth in murine prostate cancer xenograft models. We conducted a noncomparative, randomized, phase II study evaluating the antitumor efficacy of two doses oral men with metastatic cancer. Patients Methods. randomly assigned 46 chemotherapy-naïve castration-resistant (CRPC) to receive low-dose (200 mg/day) or high-dose (600 until disease progression unacceptable toxicity. primary...
Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) in men cancer. Results Five provided evidence this update. Recommendations For low-risk who require or choose active treatment, low–dose rate (LDR) alone, EBRT and/or...
The mechanism(s) by which androgen receptor (AR) splice variants contribute to castration-resistant prostate cancer (CRPC) is still lacking.Expressions of epithelial-to-mesenchymal transition (EMT) and stem cell markers were molecularly tested using (PCa) cells transfected with AR AR3 (also known as AR-V7) plasmids or siRNA, also cultured under deprivation therapy (ADT) condition. Cell migration, clonogenicity, sphere-forming capacity was assessed PCa all experimental conditions...
The CXCL12/CXCR4 axis transactivates HER2 and promotes intraosseous tumor growth. To further explore the transactivation of by CXCL12, we investigated role small GTP protein Gαi2 in Src phosphorylation lipid raft membrane microdomains significance CXCR4 prostate cancer bone We used a variety methods such as isolation, invasion assays, an vivo model intratibial growth, histomorphometry, immunohistochemistry to determine signaling effects targeting for determined that (a) EGFR is confined...